Steering to be used of VITROS SARS CoV2 Antigen CLIA based mostly Check from Ortho Medical
Diagnostics
1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay supposed for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from people who
are suspected of COVID-19 inside one to 5 days of the onset of signs, or mid-turbinate specimens
collected from asymptomatic people.
2. The assay ought to be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Built-in system from Ortho.
SKU:G61RHA20
AVAILABILITY:In Inventory with The Lowest Value within the Market
SHIPMENT:Identical Day Cargo Orders Earlier than 14
H00SIZE:20 Exams/KitSPECIFICITY:98.90%
Sort
Immunochromatography speedy check
Description
Lateral circulation immunochromatographic assay that adopted twin shade system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The check incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies particular to SARS-CoV-2 antigen on the check strains (T).
A visual black band (antibody-antigen-antibody gold conjugate advanced) seems on the check strains (T) If SARS-CoV-2 antigen is current within the specimen.
The management line (C) exhibits that check is carried out accurately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %
Functions
COVID-19, Nasopharyngeal swabs
Calibration Vary
Qualitative
VITROS SARS CoV2 antigen assay – Procedural Steps: –
Stage 1: Nasopharyngeal swab specimen assortment:
1. Gather a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab till resistance is met on the stage of the turbinate.
3. Rotate the sterile swab a number of instances in opposition to the nasopharyngeal wall & depart it in place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab pattern in VTM to the laboratory in a chilly chain.
7. The pattern will be saved at Room temperature (Under 30◦C) for as much as 24 hrs from the time of
pattern assortment or at 2 – 8◦C for as much as 48 hrs from the time of pattern assortment.
Stage 2: Pattern preparation for testing:
1. Pattern preparation must be carried out in BSL-2 stage cupboard within the Laboratory.
2. Combine the swab specimen in VTM tube effectively (vortex roughly 3-5 seconds).
3. Switch 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer right into a labelled new pattern tube.
4. Add 400 μL viral pattern to the above tube (to take care of 1:Four ratio of extraction buffer: pattern)
5. Combine effectively (Cap/Plug the pattern tube and vortex roughly 3-5 seconds).
Panbio™ COVID-19 Ag Rapid Test Device (Nasal) |
|||
| 41FK11 | Abbott | 25 Tests/Kit | EUR 95 |
|
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
|||
COVID-19 IgG & IgM antibody |
|||
| GEN-50001-50tests | Ring Bio | 50 tests | EUR 324 |
|
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
|||
COVID-19 IgG/IgM Rapid Test Kit |
|||
| UNCOV-20 | UnScience | 20T/kit | EUR 155 |
|
Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended. |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
| 3525-002mg | ProSci | 0.02 mg | EUR 171.82 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
| 3525-01mg | ProSci | 0.1 mg | EUR 436.42 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Envelope Antibody |
|||
| 3531-002mg | ProSci | 0.02 mg | EUR 171.82 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
|||
SARS-CoV-2 (COVID-19) Envelope Antibody |
|||
| 3531-01mg | ProSci | 0.1 mg | EUR 436.42 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3). |
|||
SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
| 9155P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
SARS-CoV-2 (COVID-19) Membrane Peptide |
|||
| 9157P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) Membrane Peptide |
|||
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
| 9159P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
| 9161P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
| 9163P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
SARS-CoV-2 (COVID-19) Membrane Peptide |
|||
| 9165P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) Membrane Peptide |
|||
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
| 9167P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
SARS-CoV-2 (COVID-19) Envelope Peptide |
|||
| 9169P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) Envelope Peptide |
|||
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
| 9171P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
| 9173P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
| 9175P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
| 9177P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
SARS-CoV-2 (COVID-19) NSP10 Peptide |
|||
| 9179P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) NSP10 Peptide |
|||
SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
| 9189P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
SARS-CoV-2 (COVID-19) ORF9b Peptide |
|||
| 9191P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: SARS-CoV-2 (COVID-19) ORF9b Peptide |
|||